Cited time in webofscience Cited time in scopus

Novel antitumor therapeutic strategy using CD4+ T cell-derived extracellular vesicles

Title
Novel antitumor therapeutic strategy using CD4+ T cell-derived extracellular vesicles
Author(s)
Shin, SangheeJung, InseongJung, DokyungKim, Christine S.Kang, Sung-MinRyu, SuyeonChoi, Sung-JinNoh, SoojeongJeong, JongwonLee, Beom YongPark, Jun-KookShin, JiwonCho, HanchaeHeo, Jong-IkJeong, YoungtaeChoi, Sun HaLee, Shin YupBaek, Moon-ChangYea, Kyungmoo
Issued Date
2022-10
Citation
Biomaterials, v.289
Type
Article
Author Keywords
Cancer immunotherapyExtracellular vesiclesInterleukin-2CD4+ T cellsCD8+ T cells
Keywords
INTERLEUKIN-2HELPEXOSOMES
ISSN
0142-9612
Abstract
Extracellular vesicles (EVs) mediate cell-cell crosstalk by carrying bioactive molecules derived from cells. Recently, immune cell-derived EVs have been reported to regulate key biological functions such as tumor progression. CD4+ T cells orchestrate overall immunity; however, the biological role of their EVs is unclear. This study reveals that EVs derived from CD4+ T cells increase the antitumor response of CD8+ T cells by enhancing their proliferation and activity without affecting regulatory T cells (Tregs). Moreover, EVs derived from interleukin-2 (IL2)-stimulated CD4+ T cells induce a more enhanced antitumor response of CD8+ T cells compared with that of IL2-unstimulated CD4+ T cell-derived EVs. Mechanistically, miR-25-3p, miR-155-5p, miR-215-5p, and miR-375 within CD4+ T cell-derived EVs are responsible for the induction of CD8+ T cell-mediated antitumor responses. In a melanoma mouse model, the EVs potently suppress tumor growth through CD8+ T cell activation. This study demonstrates that the EVs, in addition to IL2, are important mediators between CD4+ and CD8+ T cells. Furthermore, unlike IL2, clinically used as an antitumor agent, CD4+ T cell-derived EVs stimulate CD8+ T cells without activating Tregs. Therefore, CD4+ T cell-derived EVs may provide a novel direction for cancer immunotherapy by inducing a CD8+ T cell-mediated antitumor response. © 2022 Elsevier Ltd
URI
http://hdl.handle.net/20.500.11750/16960
DOI
10.1016/j.biomaterials.2022.121765
Publisher
Elsevier
Related Researcher
  • 정영태 Jeong, Youngtae
  • Research Interests Stem cells; Cancer; Precision medicine; Regenerative medicine; Nrf2; antioxidant
Files in This Item:

There are no files associated with this item.

Appears in Collections:
Department of New Biology Lab of Stem Cell Biology & Cancer Precision Medicine 1. Journal Articles
Department of New Biology Bio-therapeutics Design Lab 1. Journal Articles

qrcode

  • twitter
  • facebook
  • mendeley

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE